Investigational drug · Phase 2
AZD6793
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Obstructive Pulmonary Disease (COPD).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "AZD6793"
First trial start
2025
Jun 27, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD6793", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Obstructive Pulmonary Disease (COPD)
Approved drugs for the same conditions: COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD6793" as an intervention, largest first.
- A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07082738 · 987 participants (planned) · Start Jun 27, 2025 · Primary completion Aug 31, 2027
Drug: AZD6793 · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Birmingham, Alabama; Glendale, Arizona; Phoenix, Arizona · 369 sites in all
AstraZenecaAstraZeneca (AZN)
NCT05662033 · 93 participants · Start Dec 5, 2022 · Primary completion Oct 29, 2024
Drug: AZD6793; Placebo · For: Inflammatory Diseases
Sites: Harrow, United Kingdom; Wythenshawe, United Kingdom
AstraZenecaAstraZeneca (AZN)
NCT06368440 · 39 participants · Start May 15, 2024 · Primary completion Dec 23, 2024
Drug: AZD6793; AZD6793 and 1 more · For: Healthy Participants
Sites: Glendale, California
AstraZenecaAstraZeneca (AZN)
NCT07433062 · 28 participants (planned) · Start Jan 14, 2026 · Primary completion Jun 18, 2026
Drug: AZD6793; AZD6793 Placebo · For: Type 2 Diabetes Mellitus
Sites: Neuss, Germany
AstraZenecaAstraZeneca (AZN)
NCT06494644 · 17 participants · Start Jul 23, 2024 · Primary completion Oct 5, 2024
Drug: AZD6793; Itraconazole and 1 more · For: Healthy Participants
Sites: Berlin, Germany
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Obstructive Pulmonary Disease (COPD)
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- HSK39004 DryPhase 34 trials
Haisco Pharmaceutical Group Co., Ltd. · Chronic Obstructive Lung Disease (COLD), COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD)
- AstegolimabPhase 33 trials
Roche (Genentech) · Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD)
- HSK31858Phase 33 trials
Haisco Pharmaceutical Group Co., Ltd. · Non-cystic Fibrosis Bronchiectasis, Asthma Bronchiale, Bronchiectasis
- HSK39004 Dry SimulantPhase 32 trials
Haisco Pharmaceutical Group Co., Ltd. · COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD)
- JKN2401Phase 31 trial
Joincare Pharmaceutical Group Industry Co., Ltd · Chronic Obstructive Pulmonary Disease (COPD)
- PRA-216Phase 22 trials
Prana Therapies Inc · Chronic Obstructive Pulmonary Disease (COPD), Mild to Moderate Asthma
- EXPD-101FXS7553Phase 21 trial
Expedition Therapeutics, Inc · Chronic Obstructive Pulmonary Disease (COPD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.